F-star Therapeutics, Inc.

Invox Pharma Limited

F-star Delta Limited

Katy Louise Everett

Mihriban Tuna

Miguel Gaspar

Francisca Wollerton Van Horck

Matthew Kraman

Katarzyna Kmiecik

Natalie Fosh

Jamie Iain Campbell

Nikole Sandy

Mustapha Faroudi

Barbara Hebeis

Sandra Uhlenbroich

Delphine Buffet

The application relates to specific binding members that bind OX40. The specific binding members comprise an OX40 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

Fc binding fragments comprising an OX40 antigen-binding site

The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.

LAG-3 binding members

The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy.

Binding molecules binding PD-L1 and LAG-3

Growing community of inventors

Cambridge, United Kingdom

Katy Louise Everett